New milestones ahead in complement-targeted therapy.

No abstract is available for this paper.

• Publication year

  2016

• Venue

  Seminars in Immunology

• Publication date

  2016-06-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/j.smim.2016.06.001PMID 27321574PMCID PMC5404743
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• The complement system in cancer: Ambivalence between tumour destruction and promotion.

  2017cited by this paper
• Ocular complement activation and inhibition in rodent models of endotoxin-induced uveitis

  2016cited by this paper
• Generation and characterization of CLG561: a fully-human, anti-properdin Fab for the treatment of age-related macular degeneration

  2016cited by this paper
• Selectivity of C3-opsonin targeted complement inhibitors: A distinct advantage in the protection of erythrocytes from paroxysmal nocturnal hemoglobinuria patients.

  2016cited by this paper
• A novel oral small molecule Factor D inhibitor blocks complement activation in the blood and ocular tissues

  2016cited by this paper
• The paradoxical roles of C1q and C3 in autoimmunity.

  2016cited by this paper
• Paroxysmal nocturnal hemoglobinuria in the era of complement inhibition

  2016cited by this paper
• Small-molecule factor D inhibitors selectively block the alternative pathway of complement in paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome

  2016cited by this paper
• Further studies of the down‐regulation by Factor I of the C3b feedback cycle using endotoxin as a soluble activator and red cells as a source of CR1 on sera of different complotype

  2016cited by this paper
• Age-related macular degeneration: Complement in action.

  2016cited by this paper
• Therapeutic control of complement activation at the level of the central component C3.

  2016cited by this paper
• Impact of eculizumab treatment on paroxysmal nocturnal hemoglobinuria: a treatment versus no‐treatment study

  2016cited by this paper
• Systemic Lupus Erythematosus and Deficiencies of Early Components of the Complement Classical Pathway

  2016cited by this paper
• Complement in disease: a defence system turning offensive

  2016cited by this paper
• Inhibition of pre-existing natural periodontitis in non-human primates by a locally administered peptide inhibitor of complement C3.

  2016cited by this paper
• Targeting mechanisms at sites of complement activation for imaging and therapy.

  2016cited by this paper
• Structural basis for therapeutic inhibition of complement C5

  2016cited by this paper
• Therapeutic targeting of complement to modify disease course and improve outcomes in neurological conditions.

  2016cited by this paper
• Assessment of human antihuman antibodies to eculizumab after long‐term treatment in patients with paroxysmal nocturnal hemoglobinuria

  2016cited by this paper
• Current treatment options for hereditary angioedema due to C1 inhibitor deficiency

  2016cited by this paper
• Inhibition of the alternative complement pathway by antisense oligonucleotides targeting complement factor B improves lupus nephritis in mice.

  2016cited by this paper
• The mammalian complement system as an epitome of host–pathogen genetic conflicts

  2016cited by this paper
• Using an in vitro xenoantibody-mediated complement-dependent cytotoxicity model to evaluate the complement inhibitory activity of the peptidic C3 inhibitor Cp40.

  2016cited by this paper
• Small Molecule Factor D Inhibitors Block Complement Activation in Paroxysmal Nocturnal Hemoglobinuria and Atypical Hemolytic Uremic Syndrome

  2015cited by this paper
• Complement in therapy and disease: Regulating the complement system with antibody-based therapeutics.

  2015cited by this paper
• Contribution of the complement Membrane Attack Complex to the bactericidal activity of human serum.

  2015cited by this paper
• Complement inhibition decreases early fibrogenic events in the lung of septic baboons

  2015cited by this paper
• Complement Deficiency Promotes Cutaneous Wound Healing in Mice

  2015cited by this paper
• A Subcutaneously Administered Investigational RNAi Therapeutic (ALN-CC5) Targeting Complement C5 for Treatment of PNH and Complement-Mediated Diseases: Interim Phase 1 Study Results

  2015cited by this paper
• Complement System Part II: Role in Immunity

  2015cited by this paper
• Complement Interception Across Humoral Incompatibility in Solid Organ Transplantation: A Clinical Perspective.

  2015cited by this paper
• An anticomplement agent that homes to the damaged brain and promotes recovery after traumatic brain injury in mice

  2015cited by this paper
• The role of complement in C3 glomerulopathy.

  2015cited by this paper
• Attenuation of Staphylococcus aureus–Induced Bacteremia by Human Mini-Antibodies Targeting the Complement Inhibitory Protein Efb

  2015cited by this paper
• The emerging role of complement inhibitors in transplantation.

  2015cited by this paper
• Atypical aHUS: State of the art.

  2015cited by this paper
• Complement Involvement in Periodontitis: Molecular Mechanisms and Rational Therapeutic Approaches.

  2015cited by this paper
• The role of complement in neurological and neuropsychiatric diseases

  2015cited by this paper
• Immunobiological barriers to xenotransplantation.

  2015cited by this paper
• Compstatin: a C3‐targeted complement inhibitor reaching its prime for bedside intervention

  2015cited by this paper
• Therapeutic C3 inhibitor Cp40 abrogates complement activation induced by modern hemodialysis filters.

  2015cited by this paper
• Contact activation of C3 enables tethering between activated platelets and polymorphonuclear leukocytes via CD11b/CD18

  2015cited by this paper
• Applying complement therapeutics to rare diseases.

  2015cited by this paper
• Compstatin analog Cp40 inhibits complement dysregulation in vitro in C3 glomerulopathy.

  2015cited by this paper
• The complement system and toll-like receptors as integrated players in the pathophysiology of atherosclerosis.

  2015cited by this paper
• Complement, a target for therapy in inflammatory and degenerative diseases

  2015cited by this paper
• Genetically engineered fusion of MAP‐1 and factor H domains 1–5 generates a potent dual upstream inhibitor of both the lectin and alternative complement pathways

  2015cited by this paper
• Safety and Pharmacokinetics of the Complement Inhibitor TT30 in a Phase I Trial for Untreated PNH Patients

  2015cited by this paper
• The Complement Receptor C5aR Controls Acute Inflammation and Astrogliosis following Spinal Cord Injury

  2015cited by this paper
• Complement System Part I – Molecular Mechanisms of Activation and Regulation

  2015cited by this paper
• First in Human Single-Ascending Dose Study: Safety, Biomarker, Pharmacokinetics and Exposure-Response Relationships of ALXN1210, a Humanized Monoclonal Antibody to C5, with Marked Half-Life Extension and Potential for Significantly Longer Dosing Intervals

  2015cited by this paper
• Genetic variants in C5 and poor response to eculizumab.

  2014cited by this paper
• Opportunity Cost of Funding Drugs for Rare Diseases

  2014cited by this paper
• A Humanized Antibody That Regulates the Alternative Pathway Convertase: Potential for Therapy of Renal Disease Associated with Nephritic Factors

  2014cited by this paper
• Complement C 5 a receptor facilitates cancer metastasis by altering T cell responses in the metastatic niche

  2014cited by this paper
• Complement — tapping into new sites and effector systems

  2014cited by this paper
• The role of complement in mAb-based therapies of cancer.

  2014cited by this paper
• Peptide inhibitors of C3 activation as a novel strategy of complement inhibition for the treatment of paroxysmal nocturnal hemoglobinuria.

  2014cited by this paper
• Generation and Characterization of LFG316, A Fully-Human Anti-C5 Antibody for the Treatment of Age-Related Macular Degeneration

  2014cited by this paper
• Complement c5a receptor facilitates cancer metastasis by altering T-cell responses in the metastatic niche.

  2014cited by this paper
• Complement Inhibition in Cynomolgus Monkeys by Anti–Factor D Antigen-Binding Fragment for the Treatment of an Advanced Form of Dry Age-Related Macular Degeneration

  2014cited by this paper
• Humanized cobra venom factor: structure, activity, and therapeutic efficacy in preclinical disease models.

  2014cited by this paper
• Genetic and Intervention Studies Implicating Complement C3 as a Major Target for the Treatment of Periodontitis

  2014cited by this paper
• Conjugation to Albumin‐Binding Molecule Tags as a Strategy to Improve Both Efficacy and Pharmacokinetic Properties of the Complement Inhibitor Compstatin

  2014cited by this paper
• Complement in paroxysmal nocturnal hemoglobinuria: exploiting our current knowledge to improve the treatment landscape

  2014cited by this paper
• Complement activation-related pseudoallergy: a stress reaction in blood triggered by nanomedicines and biologicals.

  2014cited by this paper
• Soluble CR1 therapy improves complement regulation in C3 glomerulopathy.

  2013cited by this paper
• CR2-mediated targeting of complement inhibitors: bench-to-bedside using a novel strategy for site-specific complement modulation.

  2013cited by this paper
• Long-term safety and efficacy of sustained eculizumab treatment in patients with paroxysmal nocturnal haemoglobinuria

  2013cited by this paper
• Complement blockade with a C1 esterase inhibitor in paroxysmal nocturnal hemoglobinuria.

  2013cited by this paper
• An Engineered Construct Combining Complement Regulatory and Surface-Recognition Domains Represents a Minimal-Size Functional Factor H

  2013cited by this paper
• Nonfunctional Variant 3 Factor H Binding Proteins as Meningococcal Vaccine Candidates

  2013cited by this paper
• Role of complement in host-microbe homeostasis of the periodontium.

  2013cited by this paper
• A Novel C5a-neutralizing Mirror-image (l-)Aptamer Prevents Organ Failure and Improves Survival in Experimental Sepsis

  2013cited by this paper
• Complement in Immune and Inflammatory Disorders: Therapeutic Interventions

  2013cited by this paper
• Complement modulates the cutaneous microbiome and inflammatory milieu

  2013cited by this paper
• Complement inhibition in cancer therapy.

  2013cited by this paper
• Progress and Trends in Complement Therapeutics.

  2013cited by this paper
• Combined Inhibition of Complement (C5) and CD14 Markedly Attenuates Inflammation, Thrombogenicity, and Hemodynamic Changes in Porcine Sepsis

  2013cited by this paper
• New analogs of the clinical complement inhibitor compstatin with subnanomolar affinity and enhanced pharmacokinetic properties.

  2013cited by this paper
• Eculizumab in the treatment of atypical haemolytic uraemic syndrome and other complement-mediated renal diseases

  2013cited by this paper
• Rational Engineering of a Minimized Immune Inhibitor with Unique Triple-Targeting Properties

  2013cited by this paper
• The role of complement in trauma and fracture healing.

  2013cited by this paper
• Complement in Immune and Inflammatory Disorders: Pathophysiological Mechanisms

  2013cited by this paper
• Factor D Inhibitors for the Treatment of AMD: Patent Highlight.

  2012cited by this paper
• The role of complement in the early immune response to transplantation

  2012cited by this paper
• Manipulating the mediator: modulation of the alternative complement pathway C3 convertase in health, disease and therapy.

  2012cited by this paper
• Autoregulation of thromboinflammation on biomaterial surfaces by a multicomponent therapeutic coating

  2012cited by this paper
• Targeted complement inhibition as a promising strategy for preventing inflammatory complications in hemodialysis.

  2012cited by this paper
• Bride and groom in systemic inflammation--the bells ring for complement and Toll in cooperation.

  2012cited by this paper
• Complement dysregulation and disease: from genes and proteins to diagnostics and drugs.

  2012cited by this paper
• Inhibiting Alternative Pathway Complement Activation by Targeting the Factor D Exosite*

  2012cited by this paper
• STEC-HUS, atypical HUS and TTP are all diseases of complement activation

  2012cited by this paper
• Local Complement-Targeted Intervention in Periodontitis: Proof-of-Concept Using a C5a Receptor (CD88) Antagonist

  2012cited by this paper
• The human complement receptor type 2 (CR2)/CR1 fusion protein TT32, a targeted inhibitor of the classical and alternative pathway C3 convertases, prevents arthritis in active immunization and passive transfer models and acts by CR2-dependent targeting of CR1 regulatory activity

  2012cited by this paper
• The complotype: dictating risk for inflammation and infection

  2012cited by this paper
• Design and development of TT30, a novel C3d-targeted C3/C5 convertase inhibitor for treatment of human complement alternative pathway-mediated diseases.

  2011cited by this paper
• Innate immunity activation on biomaterial surfaces: a mechanistic model and coping strategies.

  2011cited by this paper
• C1-Inhibitor: More Than a Serine Protease Inhibitor

  2011cited by this paper
• Inhibiting the C5-C5a receptor axis.

  2011cited by this paper

• The complement - dendritic cell - endothelial cell crosstalk in vascular inflammation.

  2025cites this paper
• The complement system: Biology, pathology, and therapeutic interventions.

  2025cites this paper
• Aortic Aneurysm and Dissection: Complement and Precision Medicine in Aortic Disease.

  2025cites this paper
• The origin and polarization of Macrophages and their role in the formation of the Pre-Metastatic niche in osteosarcoma.

  2025cites this paper
• Structural insights into C3 convertase activity of the classical pathway of complement

  2025cites this paper
• Cutting edge of genetically modified pigs targeting complement activation for xenotransplantation

  2024cites this paper
• The role and treatment potential of the complement pathway in chronic pain.

  2024cites this paper
• An optimized protocol for the expression of a recombinant protein fragment of human factor B used for the production of polyclonal antibodies

  2024influential citation
• Complement networks in gene-edited pig xenotransplantation: enhancing transplant success and addressing organ shortage

  2024cites this paper
• Structural biology of complement receptors

  2023cites this paper
• Innate immune receptor C5aR1 regulates cancer cell fate and can be targeted to improve radiotherapy in tumours with immunosuppressive microenvironments

  2023cites this paper
• Targeting the complement system in geographic atrophy: mechanisms and therapeutics

  2023cites this paper
• Improving radiotherapy in immunosuppressive microenvironments by targeting complement receptor C5aR1

  2023cites this paper
• The case for complement component 5 as a target in neurodegenerative disease

  2023cites this paper
• Kidney diseases

  2022cites this paper
• Small-molecule screen reveals pathways that regulate C4 secretion in stem cell-derived astrocytes

  2022cites this paper
• Neuroimmunoactive biomaterial design

  2022cites this paper
• Immunologic deviations in recurrent spontaneous abortion mouse model

  2022cites this paper
• C3-targeted host-modulation approaches to oral inflammatory conditions.

  2022cites this paper
• The clinical significance of low complement levels in patients with catastrophic antiphospholipid syndrome: A descriptive analysis of 73 patients from the “Catastrophic antiphospholipid syndrome registry”

  2022cites this paper
• Membranoproliferative glomerulonephritis: no longer the same disease and may need very different treatment.

  2021cites this paper
• Tick‐over‐mediated complement activation is sufficient to cause basal deposit formation in cell‐based models of macular degeneration

  2021cites this paper
• Emerging Role of C5 Complement Pathway in Peripheral Neuropathies: Current Treatments and Future Perspectives

  2021cites this paper
• Enzyme kinetic and binding studies identify determinants of specificity for the immunomodulatory enzyme ScpA, a C5a inactivating bacterial protease

  2021cites this paper
• Isoquercetin Improves Inflammatory Response in Rats Following Ischemic Stroke

  2021cites this paper
• Complement as a Therapeutic Target in Systemic Autoimmune Diseases

  2021cites this paper
• Alternative Complement Pathway Inhibition Does Not Abrogate Meningococcal Killing by Serum of Vaccinated Individuals

  2021cites this paper
• C3a receptor blockade protects podocytes from injury in diabetic nephropathy.

  2020cites this paper
• Properdin Is a Key Player in Lysis of Red Blood Cells and Complement Activation on Endothelial Cells in Hemolytic Anemias Caused by Complement Dysregulation

  2020cites this paper
• Evaluation of the children with C3 glomerulopathy

  2020cites this paper
• Inflammaging and Complement System: A Link Between Acute Kidney Injury and Chronic Graft Damage

  2020cites this paper
• Biomarkers and Associated Immune Mechanisms for Early Detection and Therapeutic Management of Sepsis

  2020cites this paper
• Treatment of Rare Inflammatory Kidney Diseases: Drugs Targeting the Terminal Complement Pathway

  2020cites this paper
• Targeting C5aR1 Increases the Therapeutic Window of Radiotherapy

  2020cites this paper
• Predictors of poor kidney outcome in children with C3 glomerulopathy

  2020cites this paper
• C3-Glomerulopathie und MPGN – aktuelle Klassifikationen

  2020cites this paper
• Computational analysis of complement inhibitor compstatin using molecular dynamics

  2020influential citation
• The hijackers guide to escaping complement: Lessons learned from pathogens.

  2019cites this paper
• Functional Proteomics

  2019cites this paper
• Absence of recipient C3aR1 signaling limits expansion and differentiation of alloreactive CD8+ T cell immunity and prolongs murine cardiac allograft survival

  2019cites this paper
• Hämolytisch-urämisches Syndrom im Kindes- und Jugendalter

  2019cites this paper
• Membranoproliferative Glomerulonephritis und C3‑Glomerulopathie

  2019cites this paper
• The Emerging Role of Complement Proteins as a Target for Therapy of IgA Nephropathy

  2019cites this paper
• Therapeutic Approaches with Intravitreal Injections in Geographic Atrophy Secondary to Age-Related Macular Degeneration: Current Drugs and Potential Molecules

  2019cites this paper
• Differential effects of anaphylatoxin C5a on antigen presenting cells, roles for C5aR1 and C5aR2.

  2019cites this paper
• Significance of Complement System in Ischemic Stroke: A Comprehensive Review

  2019cites this paper
• The Challenges and Promise of Complement Therapeutics for Ocular Diseases

  2019cites this paper
• Clinical promise of next-generation complement therapeutics

  2019cites this paper
• Emerging Roles of Complement in Psychiatric Disorders

  2019cites this paper
• A rational search for discovering potential neutraligands of human complement fragment 5a (hC5a).

  2019cites this paper
• Combining MAP‐1:CD35 or MAP‐1:CD55 fusion proteins with pattern‐recognition molecules as novel targeted modulators of the complement cascade

  2019cites this paper
• Effect of a C1s Inhibitor on the Efficacy of Anti-Capsular Antibodies against Neisseria meningitidis and Streptococcus pneumoniae

  2019cites this paper
• Amentoflavone ameliorates cold stress-induced inflammation in lung by suppression of C3/BCR/NF-κB pathways

  2019cites this paper
• Complement-3a receptor involvement in peripheral and central neuropathic pain

  2019cites this paper
• Chimeric Proteins Containing MAP-1 and Functional Domains of C4b-Binding Protein Reveal Strong Complement Inhibitory Capacities

  2018cites this paper
• Endogenous DAMPs, Category III: Inducible DAMPs (Cat. III DAMPs)

  2018cites this paper
• Innate Immunity and Inflammation

  2018cites this paper
• Complement system in lung transplantation

  2018cites this paper
• Genetic biomarkers for precision medicine in age-related macular degeneration

  2018cites this paper
• Complement and Malaria in Pregnancy

  2018cites this paper
• C5aR1 regulates T follicular helper differentiation and chronic graft-versus-host disease bronchiolitis obliterans.

  2018cites this paper
• Complement activation by human red blood cell antibodies: hemolytic potential of antibodies and efficacy of complement inhibitors assessed by a sensitive flow cytometric assay

  2018cites this paper
• Proteases: Pivot Points in Functional Proteomics.

  2018cites this paper
• Complement C3-targeted gene therapy restricts onset and progression of neurodegeneration in chronic mouse glaucoma

  2018cites this paper
• The rational design of affinity-attenuated OmCI for the purification of complement C5

  2018cites this paper
• Complement Activation in Malaria Immunity and Pathogenesis

  2018cites this paper
• Properdin: A multifaceted molecule involved in inflammation and diseases.

  2018cites this paper
• Identification of complement inhibitory activities of two chemotherapeutic agents using a high‐throughput cell imaging‐based screening assay

  2018cites this paper
• Evolution of compstatin family as therapeutic complement inhibitors

  2018cites this paper
• Immunity against the Obligate Intracellular Bacterial Pathogen <named-content content-type='genus-species'>Rickettsia australis</named-content> Requires a Functional Complement System

  2018cites this paper
• Genome-Wide Association Study Reveals Variants in CFH and CFHR4 Associated with Systemic Complement Activation: Implications in Age-Related Macular Degeneration.

  2018cites this paper
• The renaissance of complement therapeutics

  2018cites this paper
• The lectin pathway in renal disease: old concept and new insights

  2018cites this paper
• The rational design of affinity attenuated OmCI 1 The rational design of affinity attenuated OmCI for the purification of Complement C5

  2018cites this paper
• Lectin-induced renal local complement activation is involved in tubular interstitial injury in diabetic nephropathy.

  2018cites this paper
• Immunity against the Obligate Intracellular Bacterial Pathogen Rickettsia australis Requires a Functional Complement System

  2018cites this paper
• The Complement System Is Critical in Maintaining Retinal Integrity during Aging

  2018cites this paper
• An unexpected player in Gaucher disease: The multiple roles of complement in disease development.

  2018cites this paper
• Cluster Analysis Identifies Distinct Pathogenetic Patterns in C3 Glomerulopathies/Immune Complex-Mediated Membranoproliferative GN.

  2017cites this paper
• Complement in clinical medicine: Clinical trials, case reports and therapy monitoring

  2017cites this paper
• Chemical Approaches to Modulating Complement-Mediated Diseases.

  2017cites this paper
• New concepts on the therapeutic control of complement anaphylatoxin receptors.

  2017cites this paper
• The complement system as a potential therapeutic target in rheumatic disease

  2017cites this paper
• Magnetic bead based assays for complement component C5.

  2017cites this paper
• TLR-Induced Murine Dendritic Cell (DC) Activation Requires DC-Intrinsic Complement

  2017cites this paper
• Anaphylatoxin C5a Regulates 6-Sulfo-LacNAc Dendritic Cell Function in Human through Crosstalk with Toll-Like Receptor-Induced CREB Signaling

  2017cites this paper
• Functional and structural characterization of four mouse monoclonal antibodies to complement C3 with potential therapeutic and diagnostic applications

  2017cites this paper
• Complement C3-Targeted Therapy: Replacing Long-Held Assertions with Evidence-Based Discovery.

  2017cites this paper
• Antibodies Against Complement Components: Relevance for the Antiphospholipid Syndrome—Biomarkers of the Disease and Biopharmaceuticals

  2017cites this paper
• This information is current as Complement Activation Requires DC-Intrinsic TLR-Induced Murine Dendritic Cell ( DC )

  2017cites this paper
• Development of Autologous C5 Vaccine Nanoparticles to Reduce Intravascular Hemolysis in Vivo.

  2017cites this paper
• Complement therapeutics.

  2016cites this paper
• Protection of host cells by complement regulators

  2016cites this paper
• Complement component C3 – The “Swiss Army Knife” of innate immunity and host defense

  2016cites this paper
• From orphan drugs to adopted therapies: Advancing C3-targeted intervention to the clinical stage.

  2016cites this paper